Polypharmacology: The rise of multitarget drugs over combination therapies

Future Medicinal Chemistry

Volumn 6, Issue 5, 2014, Pages 485-487

  Rosini, Michela ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

combination therapy; designed multiple ligands; multifactorial diseases; multitarget drugs; polypharmacology

Indexed keywords

BENZODIAZEPINE DERIVATIVE; IMATINIB;

DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; HUMAN; OUTCOME ASSESSMENT; POLYPHARMACOLOGY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS;

DRUG INTERACTIONS; HUMANS; POLYPHARMACOLOGY;

EID: 84896927108     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.25     Document Type: Review

References (20)

1. Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat. Rev. Genet. 12(1), 56-68 (2011).
2. Hornberg JJ. Simple drugs do not cure complex diseases: the need for multi-targeted drugs. In: Designing Multi-Target Drugs. Morphy RM, Harris CJ (Eds). RSC Publishing, Cambridge, UK, 1-13 (2012).
3. Ainsworth C. Networking for new drugs. Nat. Med. 17(10), 1166-1668 (2011).
4. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13(3), 297-309 (2010).
5. Borisy AA, Zimmermann GR, Lehar J. Multicomponent therapeutics. In: Polypharmacology in Drug Discovery. Peters J-U (Ed.). Wiley, NJ, USA, 315-321 (2012).
6. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10(2), 130-137 (2010).
7. Monzon JG, Dancey J. Combination agents versus multi-targeted agents - pros and cons. In: Designing Multi-Target Drugs. Morphy RM, Harris CJ (Eds). RSC Publishing, Cambridge, UK, 155-180 (2012).
8. Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347-372 (2008).
9. Evans BE, Rittle KE, Bock MG et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31(12), 2235-2246 (1988).
10. Bottegoni G, Favia AD, Recanatini M, Cavalli A. The role of fragment-based and computational methods in polypharmacology. Drug Discov. Today 17(1-2), 23-34 (2012).
11. Melchiorre C, Bolognesi ML, Minarini A, Rosini M, Tumiatti V. Polyamines in drug discovery: from the universal template approach to the multitarget-directed ligand design strategy. J. Med. Chem. 53(16), 5906-5914 (2010).
12. Hu Y, Bajorath J. How promiscuous are pharmaceutically relevant compounds? A data-driven assessment. AAPS J. 15(1), 104-111 (2013).
13. Manley PW, Zimmermann GR. Drug research leading to imatinib and beyond to nilotinib. In: Polypharmacology in Drug Discovery. Peters J-U (Ed.). Wiley, NJ, USA, 409-421 (2012).
14. Keiser MJ, Setola V, Irwin JJ et al. Predicting new molecular targets for known drugs. Nature 462(7270), 175-181 (2009).
15. Hopkins AL. Drug discovery: predicting promiscuity. Nature 462(7270), 167-168 (2009).
16. Peters JU. Polypharmacology - foe or friend? J. Med. Chem. 56(22), 8955-8971 (2013).
17. Bolognesi ML. Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem. 20(13), 1639-1645 (2013).
18. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J. Med. Chem. 53(4), 1413-1437 (2010).
19. Millan MJ. Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics 6(1), 53-77 (2009).
20. Besnard J, Ruda GF, Setola V et al. Automated design of ligands to polypharmacological profiles. Nature 492(7428), 215-220 (2012).